Metrics as of 10/16/2026, 12:50 AM (Berlin time), refresh in progress.
Rapport Therapeutics Stock
Rapport Therapeutics, Inc. Common Stock
Company data
- Sector
- Healthcare
- Industry
- Biotechnology
- Country
- United States
- CEO
- Abraham N. Ceesay
- Employees
- 84
- Market cap
- $1.4 B
- IPO
- 07/06/2024
Rapport Therapeutics, Inc. (RAPP), a healthcare and biotechnology company based in Boston, focuses on the discovery and development of innovative small molecule therapeutics for central nervous system (CNS) disorders. A cornerstone of its clinical research is the drug candidate RAP-219, an experimental molecule…
AI-generated company profile based on the figures on this page, last updated on 01/10/2026. Not investment advice.
Rapport Therapeutics stock: price history
1D
+4.4%
1W
-0.9%
1M
-30.7%
6M
-25.2%
YTD
-2.5%
1Y
+14.7%
2Y
+14.3%
5Y
–
10Y
–
Next earnings date
Next earnings date
05/11/2026 (in 19 days)
Volatility around earnings
~13% stronger price swings than usual
Rapport Therapeutics stock scores
- Valuation
Visible after free registration
- Trend
Visible after free registration
- Quality
Visible after free registration
- Dividend
Visible after free registration
- Growth
Visible after free registration
- Insider
Visible after free registration
- Earnings
Visible after free registration
- Revisions
Visible after free registration
- Sentiment
Visible after free registration
- Short Pressure
Visible after free registration
Register for free
Unlock all 11 scores
- 5 credits free on registration
- Access to virtual portfolios and watchlist
- No credit card, no payment details needed
- No subscription, no minimum term
- Our own servers in Germany, no US cloud
Deterministically calculated from financial metrics, not investment advice. Updated nightly, last on 17/10/2026.
Business model & megatrends
Average business model without a clear megatrend link or with mixed signals.
Rapport Therapeutics is a clinical-stage biopharmaceutical company focused on developing innovative small-molecule therapeutics for central nervous system disorders. At the center of its research is the drug candidate RAP-219 for the treatment of focal epilepsy as well as neuropathic pain and bipolar disorder. The pipeline also includes research approaches for treating chronic pain and hearing disorders through targeted modulation of acetylcholine receptors. The company concentrates on highly specific receptor interactions, such as AMPARs and nAChRs, to unlock new therapeutic options for neurological indications.
- Revenue model
- Transactional
- Recurring revenue
- None
- Pricing power
- Strong
- Moat
- Narrow
- Moat type
- Regulatory
- Capital intensity
- High
- Customer concentration
- Unknown
Ask the agents about Rapport Therapeutics
Analyst assessment of Rapport Therapeutics
PRICE TARGET LOW
US$50.00
CONSENSUS
US$63.75
MEDIAN
US$65.50
PRICE TARGET HIGH
US$75.00
0
STRONG BUY
5
BUY
0
HOLD
0
SELL
0
STRONG SELL
5
TOTAL · Buy
As of: 16/09/2026
Rapport Therapeutics stock metrics
P/E
-9.73
P/B
3.32
EV/EBITDA
-9.2
RETURN ON EQUITY
-13.4%
NET MARGIN
0.0%
DEBT/EQUITY
0.02
DIVIDEND YIELD
0.0%
AS OF
30/06/2026
Free float & liquidity
FREE FLOAT
47.8%
FLOAT SHARES
22,951,899
AVG. DAILY VOLUME (30D)
424,079
Insider transactions (SEC)
Ceesay Abraham
Ceesay Abraham
Gault Cheryl
Gault Cheryl
Ceesay Abraham
Attention
Price since yesterday: +4.4%
Search (Google Trends)
Institutional holders
Comparable stocks
Frequently asked questions about Rapport Therapeutics stock
What does Rapport Therapeutics do?
Rapport Therapeutics, Inc. Common Stock is a company in the Healthcare sector, Biotechnology industry, headquartered in United States.
The CEO is Abraham N. Ceesay, the company employs around 84 people.
The IPO was on 07/06/2024; the stock trades on NASDAQ under the ticker RAPP.
What do analysts say about Rapport Therapeutics stock?
5 analysts rate the stock, the consensus is Buy (as of 16/09/2026).
The average price target is US$63.75, ranging from US$50.00 to US$75.00, with a median of US$65.50.
This is an external assessment, not a statement by Market Jury.
When does Rapport Therapeutics report next?
The next earnings date is 05/11/2026.
Around past earnings, price swings were roughly 13% stronger than usual.
Does Rapport Therapeutics pay a dividend?
No, Rapport Therapeutics currently does not pay a dividend.
Which stocks are comparable to Rapport Therapeutics?
Comparable stocks include Vertex Pharmaceuticals, Moderna, Regeneron Pharmaceuticals, Revolution Medicines, Incyte, Exelixis, Neurocrine Biosciences and Summit Therapeutics.
How can I get Rapport Therapeutics stock analyzed?
Clicking "Analyze stock" lets five strategies assess Rapport Therapeutics against fixed, published rules and judge it bullish, neutral or bearish. The jury states where it disagrees. A free account starts with 5 credits, a quick check costs 1 credit, a full analysis 2 credits.
Not investment advice. Past performance is not an indicator of future results.